Tesaro, Inc. (Waltham, Massachusetts)

230 articles about Tesaro, Inc. (Waltham, Massachusetts)

• Tesaro Announces Participation At Goldman Sachs 38th Annual Global Healthcare Conference

  6/9/2017

• Tesaro Provides Business And Pipeline Update At ASCO Investor Briefing

  6/5/2017

• Why Pfizer, AstraZeneca PLC and Clovis Oncology Aren’t Interested in Tesaro

  6/2/2017

• $8 Billion+ Tesaro is Exploring a Sale But No Serious Suitors are Lining Up Just Yet

  6/2/2017

• Veristat Congratulates Tesaro On The FDA Approval Of ZEJULA

  5/30/2017

• Tesaro Announces Presentations Of Abstracts At The 2017 ASCO Annual Meeting

  5/26/2017

• Tesaro Release: National Survey Shows Resource, Emotional And Support Needs Of The Ovarian Cancer Community

  5/22/2017

• McKesson Specialty Health Selected By Tesaro To Provide ZEJULA (Niraparib), Approved For The Treatment Of Recurrent Ovarian Cancer

  5/12/2017

• Tesaro Partners With Clinigen To Initiate European Managed Access Program For Niraparib In Patients With Recurrent Ovarian Cancer

  5/11/2017

• Tesaro Announces First-Quarter 2017 Operating Results

  5/10/2017

• Tesaro Announces Submission Of Investigational New Drug Application For Anti-LAG Antibody TSR-033 To The FDA

  5/1/2017

• Tesaro Initiates Registrational Development Program For Anti-PD-1 Antibody TSR-042

  4/27/2017

• Why High-Flying M&A Target Tesaro Recently Lost More Than a Quarter of Its Value

  4/26/2017

• Tesaro To Announce First-Quarter 2017 Financial Results On May 9, 2017

  4/26/2017

• Tesaro To Announce First-Quarter 2017 Financial Results On May 9, 2017

  4/26/2017

• Tesaro Announces Participation In Two Investor Conferences

  4/26/2017

• Tesaro Announces Approval Of VARUBY (Oral Rolapitant Tablets) By European Commission (EC)

  4/26/2017

• BioLogics Selected By Tesaro As A Specialty Pharmacy Provider For ZEJULATM (Niraparib), Approved For The Treatment Of Recurrent Ovarian Cancer

  4/24/2017

• Tesaro's Path To A Billion-Dollar Blockbuster Begins With Pricing

  4/21/2017

• Tesaro Announces Availability Of Zejula (Niraparib) For Patients With Recurrent Ovarian Cancer In The U.S.

  4/20/2017